Article content material
– Mr. Tamberrino and Profound’s CEO, Arun Menawat, beforehand labored collectively at NOVADAQ earlier than it was acquired by Stryker in 2017 –
– Appointment comes as Profound continues to make remaining preparations for the everlasting CPT® Class 1 codes for TULSA going into impact in the beginning of 2025 –
TORONTO, Oct. 16, 2024 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Firm”), a commercial-stage medical system firm that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, immediately introduced the appointment of Tom Tamberrino as its new Chief Business Officer. Abbey Goodman, the Firm’s present CCO, will transition to main Profound’s strategic partnerships, persevering with to report back to the Firm’s CEO and Chairman, Arun Menawat, Ph.D.
Commercial 2
Article content material
Mr. Tamberrino has an achieved historical past of gross sales and advertising and marketing management, enterprise growth, govt administration and entrepreneurial success, most of which was gained within the U.S. healthcare business.
Mr. Tamberrino served as Vice President, Gross sales and Advertising and marketing at NOVADAQ Applied sciences Inc. (“NOVADAQ”) instantly previous to pursuing his most up-to-date entrepreneurial endeavors outdoors of the medical know-how area. Dr. Menawat, who was Chairman, President and CEO of NOVADAQ throughout Mr. Tamberrino’s tenure at that firm, instantly recruited Mr. Tamberrino to function Profound’s new CCO.
Whereas at NOVADAQ, Mr. Tamberrino helped to determine the corporate because the market chief in close to infrared fluorescence imaging for visualization of blood move and tissue perfusion, earlier than, throughout and after surgical procedures. He constructed a direct U.S. gross sales and advertising and marketing group driving an annual income run price of roughly $27 million on the finish of 2012, to greater than $82 million in annualized revenues when, in 2017, NOVADAQ was acquired by Stryker Company (“Stryker”) for roughly $701 million. Mr. Tamberrino remained till 2018 to help with the combination of the NOVADAQ enterprise into the Stryker group. Earlier in his profession, he held progressive gross sales administration positions with LifeCell Company (“LifeCell”), most lately serving as Space Director, the place he managed a 50-person gross sales staff throughout the Northeast of the US and Canada that marketed LifeCell’s regenerative tissue matrices alongside NOVADAQ’s intraoperative perfusion evaluation know-how for advanced trauma, most cancers and basic surgical procedure circumstances to colorectal, basic, plastic, transplant and trauma surgeons. Mr. Tamberrino obtained a Bachelor of Science diploma in Advertising and marketing, Minor in Psychology, from Georgetown College, and a Grasp of Enterprise Administration from Emory College.
Article content material
Commercial 3
Article content material
“That is really the second time that I’ve personally recruited Tom to construct and handle the gross sales organizations of corporations led by me as CEO – first from LifeCell to NOVADAQ and now to Profound,” stated Dr. Menawat. “The everlasting CPT® Class 1 codes for TULSA going into impact in the beginning of 2025 symbolize an anticipated main inflection level for our enterprise. Now’s the right time to usher in a gross sales and advertising and marketing govt that I’ve labored with carefully prior to now; and one who has earned my belief, respect and most significantly, confidence, within the course of. I’m honored and excited to welcome Tom to Profound.”
“As naturally inclined as I used to be to be warmly receptive to Arun’s overtures to hitch him at Profound, I needed to make certain that I might be capable to hit the bottom operating,” commented Mr. Tamberrino. “And, like many males that I had spoken to, I naturally puzzled why any prostate illness affected person who was offered with an knowledgeable alternative of obtainable therapy choices wouldn’t select TULSA given its capacity to successfully, safely and effectively deal with an unmatched number of prostate most cancers and/or benign prostatic hyperplasia (BPH) sufferers. So, I did numerous diligence. Consequently, I’m satisfied that widespread adoption of TULSA shall be pushed largely by rising affected person and doctor consciousness, and by guaranteeing TULSA might be readily accessed in essentially the most appropriate settings, together with hospitals, ASCs and personal apply places of work/amenities. Importantly, with reimbursement now on the horizon, I used to be not in a position to establish any remaining main obstacles to widespread adoption of TULSA-PRO®. I’m trying ahead to working with Arun, Abbey and the remainder of the Profound staff to maximise the great alternative we see forward.”
Commercial 4
Article content material
Commenting on Ms. Goodman’s transition to main Profound’s strategic partnerships, Dr. Menawat stated, “Over the previous a number of months, Abbey has helped lead the cost as we’ve got begun constructing nearer relationships with MR and different medical know-how corporations to assist create a complete diagnostic and interventional MRI answer to assist the Fashionable Remedy Pathway that permits for extra correct and exact prostate illness prognosis, therapy with the TULSA Process, and post-treatment follow-up. I’m excited that Abbey has accepted this newly created and necessary position, and sit up for her persevering with contributions to realizing this shared MR-centric imaginative and prescient.”
About Profound Medical Corp.
Profound is a commercial-stage medical system firm that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.
Profound is commercializing TULSA-PRO®, a know-how that mixes real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature suggestions management. The TULSA process, carried out utilizing the TULSA-PRO® system, has the potential of turning into a mainstream therapy modality throughout the whole prostate illness spectrum; starting from low-, intermediate-, or high-risk prostate most cancers; to hybrid sufferers affected by each prostate most cancers and benign prostatic hyperplasia (“BPH”); to males with BPH solely; and in addition, to sufferers requiring salvage remedy for radio-recurrent localized prostate most cancers. TULSA employs real-time MR steering for pixel-by-pixel precision to protect prostate illness sufferers’ urinary continence and sexual perform, whereas killing the focused prostate tissue through a exact sound absorption know-how that lightly heats it to kill temperature (55-57°C). TULSA is an incision- and radiation-free “one-and-done” process carried out in a single session that takes just a few hours. Nearly all prostate styles and sizes might be safely, successfully, and effectively handled with TULSA. There isn’t any bleeding related to the process; no hospital keep is required; and most TULSA sufferers report fast restoration to their regular routine. TULSA-PRO® is CE marked, Well being Canada accepted, and 510(okay) cleared by the U.S. Meals and Drug Administration (“FDA”).
Commercial 5
Article content material
Profound can also be commercializing Sonalleve®, an progressive therapeutic platform that’s CE marked for the therapy of uterine fibroids and palliative ache therapy of bone metastases. Sonalleve® has additionally been accepted by the China Nationwide Medical Merchandise Administration for the non-invasive therapy of uterine fibroids and has FDA approval below a Humanitarian Machine Exemption for the therapy of osteoid osteoma. The Firm is within the early levels of exploring extra potential therapy markets for Sonalleve® the place the know-how has been proven to have scientific software, reminiscent of non-invasive ablation of stomach cancers and hyperthermia for most cancers remedy.
Ahead-Trying Statements
This launch contains forward-looking statements relating to Profound and its enterprise which can embrace, however shouldn’t be restricted to, the expectations relating to the efficacy of Profound’s know-how within the therapy of prostate most cancers, BPH, uterine fibroids, palliative ache therapy and osteoid osteoma; and the success of Profound’s U.S. commercialization technique and actions for TULSA-PRO®. Typically, however not all the time, forward-looking statements might be recognized by way of phrases reminiscent of “plans”, “is anticipated”, “expects”, “scheduled”, “intends”, “contemplates”, “anticipates”, “believes”, “proposes” or variations (together with unfavourable variations) of such phrases and phrases, or state that sure actions, occasions or outcomes “could”, “might”, “would”, “would possibly” or “will” be taken, happen or be achieved. Such statements are primarily based on the present expectations of the administration of Profound. The forward-looking occasions and circumstances mentioned on this launch, could not happen by sure specified dates or in any respect and will differ materially because of recognized and unknown danger components and uncertainties affecting the Firm, together with dangers relating to the medical system business, regulatory approvals, reimbursement, financial components, the fairness markets usually and dangers related to development and competitors. Though Profound has tried to establish necessary components that might trigger precise actions, occasions or outcomes to vary materially from these described in forward-looking statements, there could also be different components that trigger actions, occasions or outcomes to vary from these anticipated, estimated or supposed. No forward-looking assertion might be assured. Besides as required by relevant securities legal guidelines, forward-looking statements converse solely as of the date on which they’re made and Profound undertakes no obligation to publicly replace or revise any forward-looking assertion, whether or not because of new data, future occasions, or in any other case, aside from as required by regulation.
For additional data, please contact:
Stephen Kilmer
Investor Relations
skilmer@profoundmedical.com
T: 647.872.4849
Article content material